An agile & highly customizable
toolbox for drug discovery
Obtain highly translational in-vivo data on the anti-metastatic effect of your compounds in just 5 days.
Our unique ZTX®platform shortening time for drug discovery by providing in-vivo data on tumor regression and metastasis inhibition of compounds within 5 days
The fast development of the embryo enables rapid vascularization of the developed microtumor, allowing cells to disseminate from the primary tumor site to the vasculature and the surrounding tissues.
Metastatic cells will disseminate from the primary site into the vasculature and to the hematopoietic site in the embryo´s tail, where the metastatic cells will migrate to the tissue.
Accelerate the discovery of new therapeutic agents that target cancer metastasis
How it works
- The fast development of the embryo enables rapid vascularization of the developed microtumor, allowing cells to disseminate from the primary tumor site to the vasculature and to the surrounding tissues.
Output
- Evaluation of the anti-metastatic efficacy of your drug candidates.
- The potential of the added compounds to inhibit both local and distal metastasis.
Screening of constructs
- Xenografts were generated from a lung cancer PDX model
- Human PBMC from a healthy donor was intravenously administrated
- Testing different constructs administered by co-injection with the tumor cells
Constructs were evaluated according to their ability to reduce the tumor size and inhibit metastasis.
ZTX® is a prognostic tool for validation of Epithelial Ovarian Cancer treatment
Study outline
Xenografts were generated from primary biopsies of patients (n=19) with epithelial ovarian cancer and metastatic dissemination was evaluated.
Results
High metastatic dissemination in the ZTX®platform (mets >5) correlated to the development of an advanced disease stage in the patients (orange bars).
Outcome
Tool for health care to predict prognosis and individualize treatment.